| __timestamp | Incyte Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 10337679 |
| Thursday, January 1, 2015 | 196614000 | 18187286 |
| Friday, January 1, 2016 | 303251000 | 24758063 |
| Sunday, January 1, 2017 | 366406000 | 23666957 |
| Monday, January 1, 2018 | 434407000 | 30099855 |
| Tuesday, January 1, 2019 | 468711000 | 64947625 |
| Wednesday, January 1, 2020 | 516922000 | 186363444 |
| Friday, January 1, 2021 | 739560000 | 272611040 |
| Saturday, January 1, 2022 | 1002140000 | 358782000 |
| Sunday, January 1, 2023 | 1161300000 | 409864000 |
| Monday, January 1, 2024 | 1242157000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Incyte Corporation and Intra-Cellular Therapies, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Incyte's SG&A expenses surged by over 600%, peaking at $1.16 billion in 2023. This reflects a strategic expansion, possibly to support its growing pipeline and market presence. In contrast, Intra-Cellular Therapies, Inc. maintained a more conservative growth in SG&A costs, increasing by approximately 3,860% to $410 million in the same period. This suggests a focused investment in key areas while maintaining cost efficiency. The data highlights the importance of balancing growth with cost management in the biotech sector, offering valuable insights for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Intra-Cellular Therapies, Inc.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Incyte Corporation
Sanofi and Incyte Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Cost of Revenue Trends: Incyte Corporation vs Intra-Cellular Therapies, Inc.
Incyte Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation
Intra-Cellular Therapies, Inc. or Pharming Group N.V.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation